APTO - Aptose Drifting Ahead Of Real Data From Its Intriguing Clinical Assets

I’ve tried to go to some lengths in the past to emphasize the risks that come with an investment in Aptose Biosciences (APTO) – a small biotech that has only recently seen its two lead compounds go into the clinic. Not only is there the ever-present risk of clinical trial failure (the large majority of Phase I cancer compounds fail) and the meaningful risk of further dilutive financing, but there’s a less-appreciated risk of investor sentiment (boredom, really), as biotechs can drift lower without positive data to keep investors engaged.

I continue to

Read more ...